| Literature DB >> 29688846 |
Karim N Daou1, Maram B Hakoum2, Assem M Khamis2, Lama Bou-Karroum3, Ahmed Ali4, Joseph R Habib5, Aline T Semaan1, Gordon Guyatt6, Elie A Akl7,8,9.
Abstract
BACKGROUND: Public health journals need to have clear policies for reporting the funding of studies and authors' personal financial and non-financial conflicts of interest (COI) disclosures. This study aims to assess the policies of public health journals on reporting of study funding and the disclosure of authors' COIs.Entities:
Keywords: Conflict of interest; Funding; Journal policy; Public health
Mesh:
Year: 2018 PMID: 29688846 PMCID: PMC5913791 DOI: 10.1186/s12889-018-5456-z
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Flow diagram for selection of journals
General characteristics of the journals (N = 173)
| n (%) | |
|---|---|
| Impact factor [median (IQR)] | 1.63 (1.13–2.55) |
| Listed under a category in addition to “Public, Environmental and Occupational Health” category | 92 (53) |
| | 20 (12) |
| | 15 (9) |
| | 10 (6) |
| Publisher | |
| | 25 (15) |
| | 18 (10) |
| | 14 (8) |
| | 14 (8) |
| | 12 (7) |
| | 9 (5) |
| | 8 (5) |
| | 6 (4) |
| | 4 (2) |
| | 4 (2) |
| | 3 (2) |
| | 56 (32) |
| Member of the ICMJE a | 37 (21) |
| Affiliated with a professional organization | 129 (75) |
| Member of the Committee on Publication Ethics (COPE) | 115 (67) |
| Requires compliance with at least one of the reporting statements | 67 (39) |
aICMJE International Committee of Medical Journal Editors
General characteristics of the journals’ policies on reporting of funding information (N = 155)
| n (%) | |
|---|---|
| Policy is specific to: | |
| | 143 (92) |
| | 5 (3) |
| | 7 (5) |
| Reported procedures on dealing with non-reporting or under-reporting of funding | 0 (0) |
| Submission form of funding information | |
| | 114 (74) |
| | 97 (63) |
| | 24 (16) |
| | 7 (5) |
| | 6 (4) |
| Distinguished between “funder” and “sponsor”a | 18 (12) |
aSponsor: an individual, academic institution, company or governmental agency that takes responsibility for and initiates a clinical investigation. Funder: an individual or organization that provides money for a study
Elements of the funding information required by the policies (N = 155)
| n (%) | |
|---|---|
| Phase(s) of the research study for which reporting of funding is required | |
| | 136 (88) |
| | 18 (12) |
| | 13 (8) |
| | 3 (2) |
| | 0 (0) |
| Specification of types of funding sources | |
| | 134 (87) |
| | 15 (10) |
| | 10 (7) |
| | 10 (7) |
| | 1 (1) |
| | 0 (0) |
| | 1 (1) |
| Required the disclosure of whether a not-for-profit funding source is supported by a for-profit entity | 18 (12) |
| Types of funding to be reported | |
| | 82 (53) |
| | 15 (10) |
| | 4 (3) |
| | 4 (3) |
| | 66 (43) |
| Amount of monetary support to be reported ( | |
| | 82 (100) |
| | 0 (0) |
| | 0 (0) |
| Additional information (if policy requirement of reporting on provision of supplies) (N = 15) | |
| | 9 (60) |
| | 6 (40) |
| | 0 (0) |
| | 0 (0) |
Fig. 2Percentage of policies requiring the reporting of the role of funder for the different steps of the research (N = 36)
Policies on authors to report on having independent and full control in at least one of the steps of the research process (N = 4)
| Independent and full control in any step of the research study (N = 4) | n (%) |
|---|---|
| | 1 (25) |
| | 1 (25) |
| | 2 (50) |
| | 1 (25) |
| | 0 (0) |
| | 0 (0) |
| | 0 (0) |
| | 0 (0) |
| | 2 (50) |
| | 1 (25) |
| | 1 (25) |
| | 0 (0) |
Characteristics of conflict of interest (COI) disclosure policy (N = 163)
| n (%) | |
|---|---|
| COI disclosure policy | |
| | 125 (77) |
| | 8 (5) |
| | 30 (18) |
| Timing of COI disclosure | |
| | 159 (98) |
| | 9 (6) |
| | 3 (2) |
| Form of COI disclosure | |
| | 149 (91) |
| | 24 (15) |
| | 24 (15) |
| | 9 (6) |
| | 6 (4) |
| | 2 (1) |
| Location of COI disclosure | |
| | 96 (59) |
| | 95 (58) |
| | 61 (37) |
| Via | 2 (1) |
| | 8 (5) |
| Making of COI disclosures publically available | |
| | 82 (50) |
| | 81 (50) |
| | 0 (0) |
| | 0 (0) |
| | 0 (0) |
| Requested COI disclosure related to | |
| | 137 (84) |
| | 7 (4) |
| | 26 (16) |
| Effect of COI disclosures on the editorial process described | 31 (19) |
| Authors may be contacted for more details on disclosed COI | 18 (11) |
| COI disclosure may be verified following revision or acceptance | 11 (7) |
| Procedures to verify authors’ COI disclosures described | 0 (0) |
| Effect of not disclosing COI on editorial process described | 16 (10) |
a ICMJE International Committee of Medical Journal Editors
Journal policy requirements for financial conflict of interest (COI) disclosure (N = 163)
| n (%) | |
|---|---|
| Disclosure of financial relationships | 145 (89%) |
| | 145 (89) |
| | 40 (25) |
| | 17 (10) |
| | 18 (11) |
| | 1 (0) |
| Types of financial disclosure | |
| | 83 (51) |
| | 73 (45) |
| | 73 (45) |
| | 70 (43) |
| | 53 (33) |
| | 50 (31) |
| | 47 (29) |
| | 37 (23) |
| | 26 (16) |
| | 4 (3) |
| | 40 (25) |
| | 28 (17) |
| Duration for which to disclose financial COI | |
| | 142 (87) |
| | 20 (12) |
| | 1 (1) |
| Number of months of required duration ( | |
| | 0 (0) |
| | 0 (0) |
| | 1 (5) |
| | 18 (90) |
| | 0 (0) |
| | 1 (5) |
| | 0 (0) |
| Time frame for financial COI disclosure | |
| | 11 (7) |
| | 5 (3) |
| | 4 (3) |
| Required disclosure of financial COI in the near future | 12 (7) |
| Required duration of financial COI outside submitted work | 1 (0) |
| Explicitly required source of financial benefit | 64 (39) |
| Required monetary value of financial benefit | |
| | 162 (100) |
| | 1 (0) |
| | 0 (0) |
| Required disclosure of any patents | 63 (41) |
Journal policy requirements for non-financial conflict of interest (COI) disclosure (N = 163)
| n (%) | |
|---|---|
| Required disclosure of the following non-financial COI in the “exact wording” ( | 92 (56) |
| | 71 (44) |
| | 54 (33) |
| | 33 (20) |
| | 22 (14) |
| | 22 (14) |
| | 21 (13) |
| | 20 (12) |
| | 16 (10) |
| | 13 (8) |
| | 11 (7) |
| | 11 (7) |
| | 10 (6) |
| | 7 (4) |
| | 7 (4) |
| | 6 (4) |